IQVIA and CEPI Collaborate to Strengthen Global Research Preparedness to Advance the 100 Days Mission streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI s 100 Days Mission tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
BioNTech is initiating a Phase 1/2 clinical trial of the mRNA-based mpox vaccine program, BNT166The Coalition for Epidemic Preparedness Innovations (CEPI) commits funding of up to $90 million for the
BioNTech is initiating a Phase 1/2 clinical trial of the mRNA-based mpox vaccine program, BNT166The Coalition for Epidemic Preparedness Innovations (CEPI) commits funding of up to $90 million for the development of
· CEPI to provide up to $4.98 USD million to Houston Methodist Research Institute-led consortium to use artificial intelligence for design of vaccines to fight diseases with pandemic potential.
· The project will support a consortium, led by HMRI, to design potential antigenic targets for up to 10 priority virus families with epidemic or pandemic potential. Laboratory-based tests will then be used to verify antigen designs for possible further development.
· Consortium will include The University of Texas, Austin, The University of Texas Medical Branch, J Craig Venter Research Institute, La Jolla Institute, and Argonne National Laboratory (University of Chicago).